Elicio Therapeutics, Inc. (ELTX)Healthcare | Biotechnology | Boston, United States | NasdaqCM
2.84 USD
-0.16
(-5.333%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.89 +0.05 (1.743%) ⇧ (Aug. 28, 2026, 7:34 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:07 a.m. EDT
The investment case for Elicio Therapeutics is currently broken by a catastrophic failure in its core clinical narrative. The company's stock has plummeted nearly 90% over the last four years, driven by a disastrous Phase 2 trial miss in pancreatic cancer that shattered hopes for its lead asset, ELI-002. This is not merely a temporary setback; the data confirms the drug failed its primary endpoint, rendering the current valuation a value trap rather than a bargain. Fundamentally, the business is hemorrhaging cash with negative free cash flow and no revenue, while the balance sheet remains fragile despite a modest cash reserve. The market has already priced in the worst-case scenario, yet the recent news of further disappointing data suggests the pain is far from over. With no dividend to provide income and a management team seemingly unable to pivot the pipeline effectively, there is no catalyst for recovery. The options market reflects this despair perfectly, with traders buying insurance against further collapse rather than betting on a rebound. Until a new, viable mechanism is proven in the clinic, this remains a speculative holding with no margin of safety. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 1.242660 |
| MSTL | 1.396633 |
| AutoETS | 1.404654 |
| AutoTheta | 1.434600 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 21% |
| H-stat | 1.38 |
| Ljung-Box p | 0.490 |
| Jarque-Bera p | 3.760834100501912e-200 |
| Excess Kurtosis | 20.55 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 178.254 |
| Market Cap | 74,640,544 |
| Forward P/E | -1.31 |
| Beta | 1.88 |
| Previous Name | Angion Biomedica Corp. |
| Website | https://elicio.com |
As of Aug. 22, 2026, 1:07 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive put volume (3.0k contracts) compared to call volume (154 total). The flow is concentrated in deep out-of-the-money puts at the $12.50 strike for November expiration, suggesting a fear of a significant gap-down event or continued decline rather than a rally. Call interest is negligible, with open interest heavily skewed toward lower strikes ($5.00), indicating a lack of bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.71014494 |
| Address1 | 451 D Street |
| Address2 | 5th Floor Suite 501 |
| All Time High | 263.0 |
| All Time Low | 2.66 |
| Ask | 3.71 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 263,300 |
| Average Daily Volume3 Month | 1,731,225 |
| Average Volume | 1,731,225 |
| Average Volume10Days | 263,300 |
| Beta | 1.877 |
| Bid | 2.16 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.362 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.84 |
| Current Ratio | 2.77 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.0 |
| Day Low | 2.84 |
| Debt To Equity | 178.254 |
| Display Name | Elicio Therapeutics |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda | -37,738,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.731 |
| Enterprise Value | 65,308,544 |
| Eps Current Year | -1.95 |
| Eps Forward | -2.165 |
| Eps Trailing Twelve Months | -2.04 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.3074 |
| Fifty Day Average Change | -0.46740007 |
| Fifty Day Average Change Percent | -0.14131948 |
| Fifty Two Week Change Percent | -71.014496 |
| Fifty Two Week High | 16.0 |
| Fifty Two Week High Change | -13.16 |
| Fifty Two Week High Change Percent | -0.8225 |
| Fifty Two Week Low | 2.66 |
| Fifty Two Week Low Change | 0.17999983 |
| Fifty Two Week Low Change Percent | 0.06766911 |
| Fifty Two Week Range | 2.66 - 16.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,535,400,000 |
| Float Shares | 19,192,344 |
| Forward Eps | -2.165 |
| Forward P E | -1.3117783 |
| Free Cashflow | -22,315,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 33 |
| Fullday Change | -0.16 |
| Fullday Change Percent | -5.33334 |
| Fullday Price | 2.8895 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.26975 |
| Held Percent Institutions | 0.16997999 |
| Implied Shares Outstanding | 26,281,882 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,685,664,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts. |
| Long Name | Elicio Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 74,640,544 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_214936128 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -37,841,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 78,845,646 |
| Number Of Analyst Opinions | 2 |
| Open | 3.0 |
| Operating Cashflow | -37,693,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 857 209 0050 |
| Post Market Change | 0.04949999 |
| Post Market Change Percent | 1.7429574 |
| Post Market Price | 2.8895 |
| Post Market Time | 1,787,960,056 |
| Prev Name | Angion Biomedica Corp. |
| Previous Close | 3.0 |
| Price Eps Current Year | -1.4564102 |
| Price Hint | 4 |
| Price To Book | 7.845304 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.552 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.16 |
| Regular Market Change Percent | -5.33334 |
| Regular Market Day High | 3.0 |
| Regular Market Day Low | 2.84 |
| Regular Market Day Range | 2.84 - 3.0 |
| Regular Market Open | 3.0 |
| Regular Market Previous Close | 3.0 |
| Regular Market Price | 2.84 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 421,120 |
| Return On Assets | -0.77882004 |
| Return On Equity | -7.74557 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 26,281,882 |
| Shares Percent Shares Out | 0.064 |
| Shares Short | 1,680,918 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,875,723 |
| Short Name | Elicio Therapeutics, Inc. |
| Short Percent Of Float | 0.082399994 |
| Short Ratio | 4.92 |
| Source Interval | 15 |
| State | MA |
| Symbol | ELTX |
| Target High Price | 23.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 16.5 |
| Target Median Price | 16.5 |
| Total Cash | 23,480,000 |
| Total Cash Per Share | 0.893 |
| Total Debt | 14,148,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.04 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.211525 |
| Two Hundred Day Average Change | -5.371525 |
| Two Hundred Day Average Change Percent | -0.6541446 |
| Type Disp | Equity |
| Volume | 421,120 |
| Website | https://elicio.com |
| Zip | 2,210 |